.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Retinal vascular diseases like neovascular age-related macular degeneration and diabetic macular edema cause major vision loss in India. While anti-VEGF therapy is the gold standard, high treatment costs often lead to patient non-adherence. The emergence of anti-VEGF biosimilars India offers a vital solution to these accessibility barriers. These biological agents provide comparable efficacy while significantly reducing the financial burden on the Indian healthcare system.
Specifically, the development of ranibizumab biosimilars has transformed the management of chorioretinal conditions. Researchers have conducted extensive multicenter trials to validate their clinical utility. These studies consistently demonstrate that biosimilars are non-inferior to their reference molecules in terms of visual and anatomical outcomes. Furthermore, the safety profiles are highly comparable. These agents show low immunogenicity and a minimal incidence of serious adverse events across various studies.
Moreover, real-world data from large Indian cohorts provides further reassurance regarding the routine use of these agents. Consequently, the availability of lower-cost alternatives has improved treatment initiation rates. Additionally, patients are more likely to complete their full course of therapy when costs remain manageable. Therefore, clinicians can confidently integrate these cost-effective options into their standard protocols to preserve vision in resource-limited settings.
Biosimilars significantly lower the cost of therapy. This improvement in affordability enhances patient access and long-term treatment adherence. They offer clinical outcomes similar to innovator drugs without compromising safety.
Yes. Phase 3 trials and large-scale real-world studies in India have confirmed that ranibizumab biosimilars have equivalent safety and efficacy. They also demonstrate low immunogenicity profiles compared to the reference products.
Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.
References
1. Chakraborty D et al. Biosimilar anti-vascular endothelial growth factor agents: Clinical outcomes, safety, and cost-effectiveness in India. Indian J Ophthalmol. 2026 May 01. doi: 10.4103/IJO.IJO_3222_25. PMID: 42054089.
2. Verma L et al. Clinical efficacy and safety of Razumab® (CESAR) study: Our experience with the world's first biosimilar Ranibizumab. Indian J Ophthalmol. 2021;69(2):347-351.
3. Sharma S et al. Long-term efficacy and safety of RazumabTM (biosimilar ranibizumab) in Indian patients with retinal diseases. Int J Clin Trials. 2022;9(4):255-262.
4. Sharma A et al. Biosimilar anti-VEGF: transforming retina treatment economics in South Asia. GaBI Online. 2023.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A review of clinical outcomes, safety, and cost-effectiveness of biosimilar anti-VEGF agents in India, highlighting their role in improving retinal care....
2 months ago
Andhra Pradesh reported 10 new Covid-19 cases, taking the state tally to 49 while deaths remain at four. With 24 patients hospitalized and 16 under home isolation, the Health Department has intensified monitoring. Medical professionals should review regional distribution, diagnostic protocols, and management plans.
Today
An 11-year Swedish registry study of 618 uterine sarcoma patients found that minimally invasive surgery yielded survival comparable to open surgery in early stages. However, adjuvant chemotherapy conferred no survival benefit in localized or advanced disease, highlighting stage and histology as key outcomes.
3 days back
A cross-sectional study evaluates post-intensive care syndrome in cardiac patients 2-4 weeks post-ICU discharge, highlighting cognitive, psychological, and functional impairments and the need for structured multidisciplinary rehabilitation.
3 days back
Anterior cruciate ligament reconstruction failure lacks uniform definition. A narrative review proposes an integrative framework incorporating objective and subjective instability, persistent pain, restricted motion, graft rupture, and secondary meniscal injury to standardize clinical reporting.
3 days back
With World Obesity Atlas data warning that over 41 million Indian children are overweight or obese, ICMR and NIN have unveiled a 10-point policy roadmap. The initiative calls for mandatory front-of-pack labeling, HFSS taxes, strict marketing bans, and healthier school environments to curb non-communicable diseases.
Today
